Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 9:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 756 matching trials from the live ClinicalTrials.gov search.
Conditions
Prostate Cancer
Interventions
Abiraterone - Usual, Abiraterone - Study
Drug
Lead sponsor
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Industry
Eligibility
22 Years to 75 Years · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rockville, Maryland
Conditions
Colorectal Neoplasms
Interventions
MicroOrganoSphere (MOS) drug screen
Device
Lead sponsor
Xilis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 4 more
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Lung Cancer and Aging: Improving Well-being for Older Adults With Lung Cancer

NCT06636721
Conditions
Lung Cancer
Interventions
LuCA Behavioral Intervention
Behavioral
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Prostate Cancer Adenocarcinoma
Interventions
30Gy (Gray) planning target volume (PTV)
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Colorado Springs, Colorado + 5 more
Conditions
Lung Cancer Diagnosis, Colorectal Cancer (Diagnosis), Prostate Cancer Diagnosis, Breast Cancer Diagnosis
Interventions
National TeleOncology
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Brooklyn, New York • Jamaica, New York • New York, New York + 1 more
Conditions
Breast Cancer, Metastatic Breast Cancer, Carcinoma of the Breast
Interventions
Survey (Participant), OpenEvidence CareConnect, Survey (Provider)
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Conditions
Breast Cancer Surgery
Interventions
Nipple Sparing Mastectomy (NSM), Skin-Sparing Mastectomy (SSM), Total (Simple) Mastectomy
Procedure
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
4,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
New Haven, Connecticut • Boston, Massachusetts • New York, New York + 2 more
Conditions
Anemia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Weekly procrit dosing, Interval Dosing
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Breast Neoplasm, Prostatic Neoplasm, Colorectal Neoplasms, Endometrial Neoplasms, Hodgkin Disease, Non Hodgkin Lymphoma
Interventions
AH-HA Tool in the EPIC EHR
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
12
States / cities
Fort Smith, Arkansas • Cedar Rapids, Iowa • Ballwin, Missouri + 8 more
Conditions
Healthy, no Evidence of Disease
Interventions
IMPACT intervention, Online education materials, survey administration
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
1,262 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Active, not recruiting Not applicable Interventional

Low GI Diet in Children and Adolescents With ALL

NCT03157323
Conditions
Acute Lymphoblastic Leukemia, Pediatric, Obesity, Pediatric
Interventions
Low Glycemic Index Diet
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
5 Years to 21 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
5
States / cities
Hartford, Connecticut • Washington D.C., District of Columbia • Buffalo, New York + 2 more
Conditions
Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Non-Hodgkin Lymphoma
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
168
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 119 more
Conditions
Multiple Myeloma
Interventions
Teclistamab, Talquetamab, Daratumumab SC
Drug
Lead sponsor
Carl Ola Landgren, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Miami, Florida
Conditions
Breast Cancer, Chemotherapy Effect, Muscle Weakness, Muscle Loss, Exercise
Interventions
Creatine
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Lung Cancer
Interventions
Virtual agent, Human agent
Device · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Durham, North Carolina
Withdrawn No phase listed Observational Accepts healthy volunteers

Optimal Management of Urinary Catheter in Gyn Onc

NCT05538273
Conditions
Urinary Retention
Interventions
Early removal of urinary catheter postoperatively, Late removal of urinary catheter postoperatively
Other
Lead sponsor
WellSpan Health
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
York, Pennsylvania
Conditions
Neoplasm
Interventions
Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg, HCC Child-Pugh A expansion cohort: Regorafenib 100 mg, HCC Child-Pugh B expansion cohort: Regorafenib 100 mg, NSCLC expansion cohort: Regorafenib 100 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Houston, Texas + 1 more
Conditions
Melanoma
Interventions
Dabrafenib, Trametinib, Placebos
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 14 more
Conditions
Oncology, Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma, Bladder Cancer
Interventions
MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
Drug
Lead sponsor
4D pharma plc
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Kansas City, Kansas • Pittsburgh, Pennsylvania • Houston, Texas + 1 more
Conditions
Leukemia, Myeloid, Chronic-Phase
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Renal Excretion, Bacterial Infections, Inflammatory Disease, Oncologic Disease
Interventions
11C-para-aminobenzoic acid PET/CT, Probenecid
Combination Product · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
Interventions
GB-4362, enfortumab vedotin (EV), Pembrolizumab
Drug
Lead sponsor
Generate Biomedicines
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Duarte, California • Irvine, California • Orlando, Florida + 7 more
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome
Interventions
Biospecimen Collection
Procedure
Lead sponsor
PedAL BCU, LLC
Other
Eligibility
Up to 22 Years
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
165
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 134 more
Conditions
Brain Tumor, Pediatric
Interventions
Online computerized cognitive training intervention focused on processing speed.
Behavioral
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
5 Years to 25 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Baltimore, Maryland